



Personal Programme

Table of Content

Welcome and introduction.....	5
Prevention of clinical decompensation in cirrhosis.....	5
Novel targets in portal hypertension.....	5
Endothelial cells in vascular liver diseases.....	5
Anticoagulation in patients with liver diseases.....	5
Statins in Cirrhosis and PHT.....	5
Intrahepatic non-cirrhotic portal hypertension: today and tomorrow.....	5
Discussion and closure.....	6
AID-LIVERNET registry - Registry for the European reference network in autoimmune liver disease.....	6
The European registry of studies on alcoholic liver disease in europe (SALVE).....	6
The European NAFLD registry.....	6
European study of the epidemiology, management and outcome of acute liver failure (EMO-ALF study).....	6
European registry data collection on cholangiocarcinoma.....	6
Long term graft outcome.....	6
Gender equality in hepatology: obstacles in career progression.....	7
The US perspective on gender equality.....	7
What can we do to promote gender equality in research?.....	7
Panel discussion.....	7
A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: a randomized controlled trial.....	8
Simvastatin ameliorates the sinusoidal microcirculatory phenotype, fibrosis and portal hypertension in aged cirrhotic rats.....	8
Noninvasive prediction of hemodynamic response to carvedilol therapy for primary prophylaxis in cirrhotic patients with esophageal varices: A prospective study.....	8
Anti-placental growth factor therapy attenuates experimental hepatopulmonary syndrome.....	8
Small-diameter covered stents do not affect efficacy but reduce hepatic encephalopathy in transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhosis.....	8
Novel diameter controlled expansion TIPS (Viatorr CX®) graft reduces readmission compared to regular covered TIPS graft and bare metal graft.....	8
Fecal microbiota transplant using a precision medicine approach is safe, Associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathy.....	8
A randomized, double-blind, clinical trial comparing lactulose, l-ornithine l-aspartate, or rifaximin, versus placebo, as primary prophylaxis of hepatic encephalopathy in cirrhotic patients with variceal bleeding.....	8
Understanding the integral role of public health for nursing care in hepatology.....	9
Specialist nurses in Europe: where do we stand?.....	9

Supporting lifestyle change through nurse-led motivation..... 9

Bringing new technologies in patients' care: smartphone for OLT patients..... 9

Discussion..... 9

Multidisciplinary HCV clinics in the DAAs era: where are the key roles for nurses and associates?..... 9

Enhancing skills of nurses in hepatology: the example of transient elastography and paracentesis..... 9

Sorafenib Nurse-Led Clinic for patients with HCC: impact on outcomes..... 9

Conclusions..... 9

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)..... 10

BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study..... 10

MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection..... 10

The Ileal Bile Acid Transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases – an ongoing multiple dose, open-label, multicentre study..... 10

Controlled attenuation parameter as an additional tool for the non-invasive prediction of first clinical decompensation in compensated advanced chronic liver disease..... 10

Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients..... 10

NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients..... 10

Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the “ANSWER” study..... 10

Wednesday, April 19, 2017 / 08:00 - 09:30

Joint workshop EASL/BAVENO/VALDIG

Elicium 1

Chair:

Annalisa BERZIGOTTI, *Switzerland*
 Pierre-Emmanuel RAUTOU, *France*
 Thomas REIBERGER, *Austria*

Cirrhosis and complications

08:00 - 08:10	Welcome and introduction
08:10 - 08:30	Prevention of clinical decompensation in cirrhosis Candid VILLANUEVA, <i>Spain</i>
08:30 - 08:50	Novel targets in portal hypertension Thomas REIBERGER, <i>Austria</i>
08:50 - 09:10	Endothelial cells in vascular liver diseases Pierre-Emmanuel RAUTOU, <i>France</i>
09:10 - 09:30	Anticoagulation in patients with liver diseases Andrea DE GOTTARDI, <i>Switzerland</i>

Wednesday, April 19, 2017 / 10:00 - 11:00

Joint workshop EASL/BAVENO/VALDIG

Elicium 1

Chair:

Annalisa BERZIGOTTI, *Switzerland*
 Pierre-Emmanuel RAUTOU, *France*
 Thomas REIBERGER, *Austria*

Cirrhosis and complications

10:00 - 10:20	Statins in Cirrhosis and PHT Juan G ABRALDES, <i>Canada</i>
10:20 - 10:40	Intrahepatic non-cirrhotic portal hypertension: today and tomorrow Jeffrey SCHOUTEN, <i>Belgium</i>

10:40 - 11:00 Discussion and closure

Thursday, April 20, 2017 / 12:00 - 13:30

Registry grants presentations

Emerald Room

Chair:

Annalisa BERZIGOTTI, *Switzerland*

Philip NEWSOME, *United Kingdom*

General hepatology

12:00 - 12:15	AID-LIVERNET registry - Registry for the European reference network in autoimmune liver disease Christoph SCHRAMM, <i>Germany</i>
12:15 - 12:30	The European registry of studies on alcoholic liver disease in europe (SALVE) Philippe MATHURIN, <i>France</i>
12:30 - 12:45	The European NAFLD registry Quentin Mark ANSTEE, <i>United Kingdom</i>
12:45 - 13:00	European study of the epidemiology, management and outcome of acute liver failure (EMO-ALF study) Kenneth J. SIMPSON, <i>United Kingdom</i>
13:00 - 13:15	European registry data collection on cholangiocarcinoma Jesus BANALES, <i>Spain</i>
13:15 - 13:30	Long term graft outcome Deirdre KELLY, <i>United Kingdom</i>

Friday, April 21, 2017 / 11:30 - 12:30

Women in Hepatology

D201

Chair:

Annalisa BERZIGOTTI, *Switzerland*

Massimo PINZANI, *United Kingdom*

General hepatology

11:30 - 11:45	Gender equality in hepatology: obstacles in career progression Giorgina MIELI-VERGANI, <i>United Kingdom</i>
11:45 - 12:00	The US perspective on gender equality Cynthia LEVY, <i>United States</i>
12:00 - 12:15	What can we do to promote gender equality in research? Eucharía MEEHAN, <i>Ireland</i>
12:15 - 12:30	Panel discussion

Friday, April 21, 2017 / 12:30 - 14:00

EASL General Assembly **Emerald Room**

- Chair:**
 Mauro BERNARDI, *Italy*
 Annalisa BERZIGOTTI, *Switzerland*
 Laurent CASTERA, *France*
 Helena CORTEZ PINTO, *Portugal*
 Alejandro FORNER, *Spain*
 Tom KARLSEN, *Norway*
 Philip NEWSOME, *United Kingdom*
 Francesco NEGRO, *Switzerland*
 Marco MARZIONI, *Italy*
 Gregoire PAVILLON, *Switzerland*
 Massimo PINZANI, *United Kingdom*
 Frank TACKE, *Germany*

EASL general assembly

Friday, April 21, 2017 / 16:00 - 18:00

Parallel session: Portal hypertension and hepatic encephalopathy **Auditorium**

- Chair:**
 Annalisa BERZIGOTTI, *Switzerland*
 Sara MONTAGNESE, *Italy*

Cirrhosis and complications

16:00 - 16:15	A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: a randomized controlled trial Grace WONG, <i>Hong Kong, China</i>
16:15 - 16:30	Simvastatin ameliorates the sinusoidal microcirculatory phenotype, fibrosis and portal hypertension in aged cirrhotic rats Raquel MAESO-DIAZ, <i>Spain</i>
16:30 - 16:45	Noninvasive prediction of hemodynamic response to carvedilol therapy for primary prophylaxis in cirrhotic patients with esophageal varices: A prospective study Hwi Young KIM, <i>Korea, South</i>
16:45 - 17:00	Anti-placental growth factor therapy attenuates experimental hepatopulmonary syndrome Sarah RAEVENS, <i>Belgium</i>
17:00 - 17:15	Small-diameter covered stents do not affect efficacy but reduce hepatic encephalopathy in transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhosis Guohong HAN, <i>China</i>
17:15 - 17:30	Novel diameter controlled expansion TIPS (Viatorr CX®) graft reduces readmission compared to regular covered TIPS graft and bare metal graft Michael PRAKTIKNJO, <i>Germany</i>
17:30 - 17:45	Fecal microbiota transplant using a precision medicine approach is safe, Associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathy Jasmohan BAJAJ, <i>United States</i>
17:45 - 18:00	A randomized, double-blind, clinical trial comparing lactulose, l-ornithine l-aspartate, or rifaximin, versus placebo, as primary prophylaxis of hepatic encephalopathy in cirrhotic patients with variceal bleeding Fatima HIGUERA-DE LA TIJERA, <i>Mexico</i>

Saturday, April 22, 2017 / 12:00 - 13:30

Multidisciplinary hepatology: what is the role of nurses and associates?

D201

Chair:

Annalisa BERZIGOTTI, *Switzerland*

Pam O'DONOGHUE, *United Kingdom*

General hepatology
 Nurses

12:00 - 12:20	Understanding the integral role of public health for nursing care in hepatology Joanne BOSANQUET, <i>United Kingdom</i>
12:20 - 12:40	Specialist nurses in Europe: where do we stand? Françoise CHARNAY-SONNEK, <i>France</i>
12:40 - 13:10	Supporting lifestyle change through nurse-led motivation Kathrin HUSI, <i>Switzerland</i>
13:10 - 13:25	Bringing new technologies in patients' care: smartphone for OLT patients Thomas BREARD, <i>France</i>
13:25 - 13:30	Discussion

Saturday, April 22, 2017 / 14:00 - 15:30

Multidisciplinary hepatology: what is the role of nurses and associates? D201

Chair:
 Annalisa BERZIGOTTI, *Switzerland*
 Pam O'DONOGHUE, *United Kingdom*

General hepatology
 Nurses

14:00 - 14:30	Multidisciplinary HCV clinics in the DAAs era: where are the key roles for nurses and associates? Curtis COOPER, <i>Canada</i>
14:30 - 14:55	Enhancing skills of nurses in hepatology: the example of transient elastography and paracentesis Marjan BIJMOLLEN, <i>Netherlands</i>
14:55 - 15:20	Sorafenib Nurse-Led Clinic for patients with HCC: impact on outcomes Pam O'DONOGHUE, <i>United Kingdom</i>
15:20 - 15:30	Conclusions Pam O'DONOGHUE, <i>United Kingdom</i>

Saturday, April 22, 2017 / 16:00 - 18:00

Late breaker session

Hall 5

Chair:

Mario U. MONDELLI, *Italy*

Dominique-Charles VALLA, *France*

General hepatology

Webcasted session

16:00 - 16:15	A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso) Christophe CORPECHOT, <i>France</i>
16:15 - 16:30	BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study Arun SANYAL, <i>United States</i>
16:30 - 16:45	MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection Nancy REAU, <i>United States</i>
16:45 - 17:00	The Ileal Bile Acid Transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases – an ongoing multiple dose, open-label, multicentre study Ulrich BAUMANN, <i>Germany</i>
17:00 - 17:15	Controlled attenuation parameter as an additional tool for the non-invasive prediction of first clinical decompensation in compensated advanced chronic liver disease Cristina MARGINI, <i>Switzerland</i>
17:15 - 17:30	Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients Alice TURNER, <i>United Kingdom</i>
17:30 - 17:45	NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients Stephen HARRISON, <i>United States</i>
17:45 - 18:00	Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the “ANSWER” study Mauro BERNARDI, <i>Italy</i>